CN114931624A - 清新宝配方 - Google Patents
清新宝配方 Download PDFInfo
- Publication number
- CN114931624A CN114931624A CN202210762308.4A CN202210762308A CN114931624A CN 114931624 A CN114931624 A CN 114931624A CN 202210762308 A CN202210762308 A CN 202210762308A CN 114931624 A CN114931624 A CN 114931624A
- Authority
- CN
- China
- Prior art keywords
- extract
- ginger
- following components
- safflower seed
- tribulus terrestris
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title abstract description 11
- 208000005069 pulmonary fibrosis Diseases 0.000 claims abstract description 20
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 17
- 235000008397 ginger Nutrition 0.000 claims abstract description 17
- 229940023866 safflower seed extract Drugs 0.000 claims abstract description 17
- 229940068797 tribulus terrestris extract Drugs 0.000 claims abstract description 17
- 230000006378 damage Effects 0.000 claims abstract description 14
- 240000006499 Flammulina velutipes Species 0.000 claims abstract description 13
- 235000016640 Flammulina velutipes Nutrition 0.000 claims abstract description 13
- 241000234314 Zingiber Species 0.000 claims description 16
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 230000002757 inflammatory effect Effects 0.000 claims description 7
- 230000002685 pulmonary effect Effects 0.000 claims description 7
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 102000009123 Fibrin Human genes 0.000 claims description 5
- 108010073385 Fibrin Proteins 0.000 claims description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 5
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 230000007691 collagen metabolic process Effects 0.000 claims description 5
- 229950003499 fibrin Drugs 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims 4
- 230000003064 anti-oxidating effect Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 abstract description 11
- 238000000034 method Methods 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 5
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 244000273928 Zingiber officinale Species 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- -1 flavonoid compounds Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000004132 lipogenesis Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 206010001889 Alveolitis Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 230000002300 anti-fibrosis Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002206 pro-fibrotic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 210000004911 serous fluid Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种清新宝配方,由以下组分构成:红花籽萃取物、藤黄果萃取物、金针菇萃取物、刺蒺藜萃取物、姜。本发明中通过采用中药药理学方法进行搭配药材,各个成分之间通过协同作用来抑制肺脏的炎症反应、减轻肺组织的损伤、减少肺脏纤维化组织的产生而发挥抗肺纤维化作用。
Description
技术领域
本发明涉及肺纤维化治疗药物技术领域,更具体的说是涉及清新宝配方。
背景技术
肺纤维化一般指在毒物、自发免疫反应、药物副反应、感染、严重外伤等不同因素刺激下引起肺部炎症反应。该病的基本病程和病理为:肺脏早期损伤之后有肺泡炎,肺泡内有浆液和细胞成分,肺间质内有大量单核细胞、淋巴细胞、浆细胞、肺泡巨噬细胞等炎症免疫细胞浸润,多种细胞因子分泌,此时肺泡结构尚完整;随着炎症免疫反应的进展,促纤维化因子生成增多或抗纤维化因子产生相对不足,炎症和异常修复导致肺间质细胞增殖,导致肺纤维化过程的细胞外基质(ECM)代谢异常,产生大量的ECM蛋白;进入晚期,肺泡结构为坚实的胶原代替,肺泡壁、气道和血管最终纤维化,严重影响肺的通气和换气功能,最终导致呼吸功能衰竭而死亡。该病的发病机理未完全阐明,目前临床上缺乏有效的治疗手段,死亡率很高。美国胸科学会(ATS)、欧洲呼吸学会(ERS)、日本呼吸学会(JRS)及拉丁美洲胸科协会(ALAT)对IPF的定义为:特发性肺纤维化(IPF)是一种原因不明,慢性、特发性、进行性肺间质纤维化的间质性肺炎。
发明内容
有鉴于此,本发明提供了一种清新宝配方用于治疗肺部纤维化、辅助修复。
为实现上述目的,本发明提供如下技术方案,由以下组分构成:红花籽萃取物、藤黄果萃取物、金针菇萃取物、刺蒺藜萃取物、姜。
优选的,在上述清新宝配方中,由以下重量组分构成:
红花籽萃取物20-30g
藤黄果萃取物15-25g
金针菇萃取物10-15g
刺蒺藜萃取物20-30g
姜10-20g。
优选的,在上述清新宝配方中,由以下重量组分构成:
红花籽萃取物20-25g
藤黄果萃取物15-20g
金针菇萃取物10-13g
刺蒺藜萃取物20-25g
姜10-15g。
优选的,在上述清新宝配方中,所述由以下重量组分构成:
红花籽萃取物22g
藤黄果萃取物17g
金针菇萃取物11g
刺蒺藜萃取物21g
姜12g。
优选的,在上述清新宝配方中,治疗肺纤维化药物可通过抗氧化抗自由基损伤、抑制炎症因子的释放抗炎性损伤、影响胶原的代谢减少肺纤维蛋白的形成3个方面发挥抑制肺纤维化的作用。
优选的,在上述清新宝配方中,各个成分功效如下:
红花籽萃取物:具有活血化瘀,扩张冠状动脉流量,疏通微循环,改善心肌缺血的作用;
藤黄果萃取物:抑制脂肪形成,增强人体的抗氧化能力;
金针菇萃取物:其乳酸脱氢酶的活力、肌糖原、肝糖原的含量均显著增加,促进新陈代谢,金针菇有效地增强机体的生物活性,促进体内新陈代谢;
刺蒺藜萃取物:含有的黄酮类化合物、生物碱和维生素等营养成分,也是人体正常代谢所必需的营养物质,被人体吸收之后可以提高身体各器官的功能,也能够增强人体的抗氧化能力;
姜:温中止呕、温肺止咳的功效。
经由上述的技术方案可知,与现有技术相比,本发明公开提供了清新宝配方,本发明中通过采用中药药理学方法进行搭配药材,各个成分之间通过协同作用来抑制肺脏的炎症反应、减轻肺组织的损伤、减少肺脏纤维化组织的产生而发挥抗肺纤维化作用。
具体实施方式
下面对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例一
本发明,由以下组分构成:红花籽萃取物、藤黄果萃取物、金针菇萃取物、刺蒺藜萃取物、姜。
为了进一步优化上述技术方案,由以下重量组分构成:
红花籽萃取物30g
藤黄果萃取物25g
金针菇萃取物15g
刺蒺藜萃取物30g
姜20g。
为了进一步优化上述技术方案,治疗肺纤维化药物通过抗氧化抗自由基损伤、抑制炎症因子的释放抗炎性损伤、影响胶原的代谢减少肺纤维蛋白的形成3个方面发挥抑制肺纤维化的作用。
实施例二
本发明,由以下组分构成:红花籽萃取物、藤黄果萃取物、金针菇萃取物、刺蒺藜萃取物、姜。
为了进一步优化上述技术方案,由以下重量组分构成:
红花籽萃取物20g
藤黄果萃取物15g
金针菇萃取物10g
刺蒺藜萃取物20g
姜10g。
为了进一步优化上述技术方案,治疗肺纤维化药物通过抗氧化抗自由基损伤、抑制炎症因子的释放抗炎性损伤、影响胶原的代谢减少肺纤维蛋白的形成3个方面发挥抑制肺纤维化的作用。
实施例三
本发明,由以下组分构成:红花籽萃取物、藤黄果萃取物、金针菇萃取物、刺蒺藜萃取物、姜。
为了进一步优化上述技术方案,由以下重量组分构成:
红花籽萃取物22g
藤黄果萃取物17g
金针菇萃取物11g
刺蒺藜萃取物21g
姜12g。
为了进一步优化上述技术方案,治疗肺纤维化药物可通过抗氧化抗自由基损伤、抑制炎症因子的释放抗炎性损伤、影响胶原的代谢减少肺纤维蛋白的形成3个方面发挥抑制肺纤维化的作用。
为了进一步优化上述技术方案,各个成分功效如下:
红花籽萃取物:具有活血化瘀,扩张冠状动脉流量,疏通微循环,改善心肌缺血的作用;
藤黄果萃取物:抑制脂肪形成,增强人体的抗氧化能力;
金针菇萃取物:其乳酸脱氢酶的活力、肌糖原、肝糖原的含量均显著增加,促进新陈代谢,金针菇有效地增强机体的生物活性,促进体内新陈代谢;
刺蒺藜萃取物:含有的黄酮类化合物、生物碱和维生素等营养成分,也是人体正常代谢所必需的营养物质,被人体吸收之后可以提高身体各器官的功能,也能够增强人体的抗氧化能力;
姜:温中止呕、温肺止咳的功效。
为了进一步优化上述技术方案,本发明中通过采用中药药理学方法进行搭配药材,各个成分之间通过协同作用来抑制肺脏的炎症反应、减轻肺组织的损伤、减少肺脏纤维化组织的产生而发挥抗肺纤维化作用。
本说明书中各个实施例采用递进的方式描述,每个实施例重点说明的都是与其他实施例的不同之处,各个实施例之间相同相似部分互相参见即可。对于实施例公开的装置而言,由于其与实施例公开的方法相对应,所以描述的比较简单,相关之处参见方法部分说明即可。
对所公开的实施例的上述说明,使本领域专业技术人员能够实现或使用本发明。对这些实施例的多种修改对本领域的专业技术人员来说将是显而易见的,本文中所定义的一般原理可以在不脱离本发明的精神或范围的情况下,在其它实施例中实现。因此,本发明将不会被限制于本文所示的这些实施例,而是要符合与本文所公开的原理和新颖特点相一致的最宽的范围。
Claims (5)
1.一种清新宝配方,其特征在于,由以下组分构成:红花籽萃取物、藤黄果萃取物、金针菇萃取物、刺蒺藜萃取物、姜。
2.根据权利要求1所述的清新宝配方,其特征在于,由以下重量组分构成:
红花籽萃取物20-30g
藤黄果萃取物15-25g
金针菇萃取物10-15g
刺蒺藜萃取物20-30g
姜10-20g。
3.根据权利要求1所述的清新宝配方,其特征在于,由以下重量组分构成:
红花籽萃取物20-25g
藤黄果萃取物15-20g
金针菇萃取物10-13g
刺蒺藜萃取物20-25g
姜10-15g。
4.根据权利要求1所述的清新宝配方,其特征在于,由以下重量组分构成:
红花籽萃取物22g
藤黄果萃取物17g
金针菇萃取物11g
刺蒺藜萃取物21g
姜12g。
5.根据权利要求1所述的清新宝配方,其特征在于,治疗肺纤维化药物通过抗氧化抗自由基损伤、抑制炎症因子的释放抗炎性损伤、影响胶原的代谢减少肺纤维蛋白的形成3个方面发挥抑制肺纤维化的作用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210762308.4A CN114931624A (zh) | 2022-06-30 | 2022-06-30 | 清新宝配方 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210762308.4A CN114931624A (zh) | 2022-06-30 | 2022-06-30 | 清新宝配方 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114931624A true CN114931624A (zh) | 2022-08-23 |
Family
ID=82868563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210762308.4A Pending CN114931624A (zh) | 2022-06-30 | 2022-06-30 | 清新宝配方 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114931624A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102580051A (zh) * | 2012-03-28 | 2012-07-18 | 丁世广 | 治疗甲型肝炎的口服液 |
CN103920114A (zh) * | 2014-03-31 | 2014-07-16 | 李树民 | 一种治疗肺纤维化的中药组合物 |
CN105902614A (zh) * | 2016-04-19 | 2016-08-31 | 王胜 | 一种含有黄芩甙的植物盐及其制备方法 |
CN111803512A (zh) * | 2020-08-25 | 2020-10-23 | 首都医科大学附属北京中医医院 | 蒺藜皂苷d在制备治疗银屑病的药物中的应用 |
-
2022
- 2022-06-30 CN CN202210762308.4A patent/CN114931624A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102580051A (zh) * | 2012-03-28 | 2012-07-18 | 丁世广 | 治疗甲型肝炎的口服液 |
CN103920114A (zh) * | 2014-03-31 | 2014-07-16 | 李树民 | 一种治疗肺纤维化的中药组合物 |
CN105902614A (zh) * | 2016-04-19 | 2016-08-31 | 王胜 | 一种含有黄芩甙的植物盐及其制备方法 |
CN111803512A (zh) * | 2020-08-25 | 2020-10-23 | 首都医科大学附属北京中医医院 | 蒺藜皂苷d在制备治疗银屑病的药物中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10195239B2 (en) | Extract of Trigonella foenum-graecum | |
JP7179888B2 (ja) | 心臓肥大および肺高血圧の治療用医薬の製造におけるカウラン化合物の使用 | |
US20220151935A1 (en) | Use of amino acid based nutrients and pharmaceutical composition containing the same | |
CN112438973A (zh) | 一种药物组合物及其应用 | |
CN107951764A (zh) | 一种具有预防口腔溃疡和修复口腔黏膜功效的中药牙膏 | |
CN109620879A (zh) | 一种清湿修复膏及其制备方法 | |
CN114931624A (zh) | 清新宝配方 | |
US20030157206A1 (en) | Fabrication method of oral care composition | |
CA2894466A1 (en) | Uses and methods for the treatment of liver diseases or conditions | |
US20170333393A1 (en) | Injectable antioxidant formulation for intravenous use of sodium ascorbate in high dosage, n-acetyl cysteine, and deferoxamine; method of administration and use for preventing injury due to reperfusion; and kit | |
CN108014106A (zh) | 卡格列净在制备用于辅助治疗特发性肺纤维化的药物中的应用 | |
KR101168981B1 (ko) | 구연산, 아연 및 엘-아르기닌을 포함하는 화상 치료용 조성물 | |
US20230181626A1 (en) | USE OF MICRO- AND NANO-MgH2 COMPOUND PARTICLES IN INHIBITION OF LEISHMANIA INFECTION AND TREATMENT OF LEISHMANIASIS | |
Reisin et al. | More rapid relief of pain with isosorbide dinitrate oral spray than with sublingual tablets in elderly patients with angina pectoris | |
Miwa et al. | Combination therapy with oral sildenafil and beraprost for pulmonary arterial hypertension associated with CREST syndrome | |
CN114432317A (zh) | 吡咯并嘧啶类化合物的用途 | |
WO2017084631A9 (zh) | 预防或治疗脂肪胰、改善脂肪胰引起的胰病变、糖尿病或其他相关病症之组合物及方法 | |
JP2023503844A (ja) | 乾癬を治療する漢方薬組成物、その製造方法及び使用 | |
GB2600668A (en) | Alpha Lipoic Acid (A-ALA) and Alpha Lipoic Acid (R-ALA) As a Pharmaceutical Product for Intravenous Application to reduce Inflammation from infection. | |
CN110251613A (zh) | 一种治疗手部脱皮的复方制剂及其制备方法 | |
KR20230002589A (ko) | 장기 손상의 예방 및 치료 | |
CN112603917B (zh) | 辣椒素酯的新用途 | |
Kenari et al. | Treatment of Chronic Acne by Persian Medicine (Temperament Modification plus Leech Therapy): A Case Report | |
CN107260833B (zh) | 一种用于治疗痤疮的中药组合物及其制备方法 | |
KR100773275B1 (ko) | 인삼 사포닌을 유효 성분으로 함유하는 심혈관 질환 치료제및 예방제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220823 |